FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 | |
|-------------|------|-------|--|

| STATEMENT | OF | CHANGES | IN BENE | FICIAL | OWNERSHIP |
|-----------------------------------------|----|---------|---------|--------|-----------|
| • · · · · · · · · · · · · · · · · · · · | • | | | | ~ |

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-02 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Hogue Dale Curtis Jr.</u> | | | | 2. Issuer Name and Ticker or Trading Symbol Alaunos Therapeutics, Inc. [TCRT] | | | | | (Che | S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------------------------|---------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|--------|-----------------------------------------------------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------|---------------------|-------|
| (Last) | , | irst) IERAPEUTICS, | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 01/20/2024 | | | | | | X | Officer (give title below) Interim CE | | | Other (sp below) | ecify |
| 2617 BISSONNET ST, SUITE 225 | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | Line) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | |
| (Street) | ON T | X | 77005 | | | | | | | | 21 | | • | • | One Reporti | ng |
| (City) | (S | tate) | (Zip) | | Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | |
| Date | | | 2. Transact Date (Month/Day | Execution Date, | | Code (Instr. | | | | 5. Amoun Securities Beneficia Owned Fo Reported | Form (D) or | | n: Direct In r Indirect E sstr. 4) C | 7. Nature of indirect Beneficial Ownership Instr. 4) | | |
| | | | | | | Code V | Amount | (A) or (D) | Price | Transacti (Instr. 3 a | | | | 11001. 41) | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Ye | Code | saction (Instr. | ction Derivative Expiration Date (Month/Day/Year) (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | | |
| Employee Stock Option (right to buy) | \$0.12 | 01/20/2024 | | A | | 600,000 | | (1) | 01/19/2034 | Common Stock | 600,000 | \$0.00 | 600,00 | 00 | D | |

Explanation of Responses:

1. In twelve equal monthly installments measured from January 20, 2024, with the first vesting occurring on February 20, 2024, subject to the Reporting Person's continued service through each such date.

/s/ Michael Wong, By PoA from 01/23/2024 Dale Curtis Hogue, Jr.

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.